Latest in News & Research
FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
Approval is for once-daily 0.3 percent roflumilast topical foam for patients 12 years and older
AI Three-Item Severity Score Can ID Eczema From Patient-Uploaded Images
AI-TIS score correlated well with TIS scores determined by board-certified dermatologists and/or allergists
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
Residual inflammation significantly linked to higher BMI, metabolic dysfunction-associated steatotic liver disease, baseline systemic inflammation
Mastocytosis Tied to Increased Risk for Skin Cancer, Especially Malignant Melanoma
Except for basal cell carcinoma, all risks remained significantly elevated when excluding the first 30 days after diagnosis
Younger Patients Exhibit Faster Radiation Dermatitis Resolution
Findings seen in cohort of 21 adults with cancer treated with radiation therapy
Why a Financial Advisor Can Be Advantageous for Doctors: Choosing the Right Kind of "Expensive"
In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...
FDA Warns of Possible Bacteria Contamination of Tattoo Inks
Infections can cause rashes, lesions, and even scarring
Socioeconomic Status Tied to New Diagnosis of Hidradenitis Suppurativa
Greater odds of new diagnosis seen in lower-SES neighborhoods in analyses adjusting for age, sex, race and ethnicity
Age, Comorbidity Score Prognostic for Skin Appendage Carcinoma
Better survival predicted with private insurance compared with Medicaid, Medicare, no insurance
Deep Learning Model Developed for Classification of Melasma Severity
Area under the curve values reached 0.93, 0.86, and 0.94 for mild, moderate, and severe melasma with GoogLeNet model
Global Burden of Atopic Dermatitis in Older Adults Is Considerable
Global prevalence of older adult AD increased from 1990 to 2021 and is expected to continue increasing to 2050
Mutation Burden in Normal Skin Increases With Narrow-Band UVB in Psoriasis
Point at which skin cancer surveillance should be offered estimated based on NB-UVB exposure, sun exposure
AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer
Leveraging whole slide embeddings from pretrained machine learning models can improve diagnosis of nonmelanoma skin cancer
FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
Patients with psoriatic arthritis are less likely to begin disease-modifying antirheumatic drug therapy
Adult Acne Linked to Higher Risk for Eating Disorders
Findings attenuated but still significant after allowing for history of anxiety, depression, body dysmorphic disorder
Risk for Secondary Cancer Higher for Primary Cutaneous B-Cell Lymphoma
Patients with pCBCL have increased risk for second primary prostate cancer and lymphoma
Ivarmacitinib Efficacious for Moderate-to-Severe Atopic Dermatitis
More patients achieved IGA score of 0 or 1 with at least a 2-grade improvement with once-daily 4-mg or 8-mg ivarmacitinib versus placebo
Launch Alert: Dupixent Approved for Chronic Spontaneous Urticaria (CSU)
New FDA approval expands treatment options for chronic spontaneous urticaria patients aged 12 years and older
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
Findings independent of autoimmune conditions or dupilumab use
FDA Approves Dupixent for Chronic Spontaneous Urticaria
Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment
Imaging Aids Management in High-Risk Cutaneous Squamous Cell Carcinoma
Unexpected imaging findings seen in 49 percent of imaged tumors, resulting in changed management in 47 percent of cases
Rilzabrutinib Beneficial for Treating Chronic Spontaneous Urticaria
Significant reductions seen in end points, including weekly Itch Severity Score, weekly Urticaria Activity Score
24 of 1200